Sanofi's Dupixent Soars to New Heights, Offsetting Vaccine Sales Decline

Sanofi's blockbuster drug Dupixent has achieved a remarkable milestone, with quarterly sales surpassing €4 billion for the first time. This surge in Dupixent's performance has helped the French pharmaceutical giant overcome a significant shortfall in vaccine sales, highlighting the drug's growing importance in Sanofi's portfolio.

Dupixent's Record-Breaking Performance

Dupixent, an anti-inflammatory agent co-developed with Regeneron, generated €4.2 billion ($4.9 billion) in sales during the third quarter of 2025, marking a 26% year-over-year increase and an 8% sequential boost. With sales in the first three quarters totaling €11.5 billion ($13.4 billion), Dupixent is on track to significantly surpass last year's impressive revenue of €13.1 billion.

The drug's success can be attributed to its expanding range of indications. Over the past 13 months, Sanofi and Regeneron have secured three new approvals for Dupixent, including treatments for chronic obstructive pulmonary disorder (COPD), chronic spontaneous urticaria (CSU), and bullous pemphigoid (BP). Brian Foard, Sanofi's specialty care chief, emphasized that growth is being driven across all eight of Dupixent's indications, with COPD emerging as the fastest-growing respiratory indication.

Vaccine Sales Decline Amid Challenging Market Conditions

While Dupixent continues to exceed expectations, Sanofi reported an 8% year-over-year decline in vaccine sales, which totaled €3.4 billion ($3.9 billion) for the quarter. The company attributed this downturn to lower vaccination rates and what Chief Financial Officer François Roger described as "negative buzz" surrounding vaccines overall.

Thomas Triomphe, Sanofi's vaccines chief, noted that the first few weeks of the flu season have shown soft vaccination rates, particularly in the United States. This trend, coupled with Sanofi's significant reliance on flu vaccines, suggests that a quick turnaround in the vaccine segment may be challenging.

Overall Financial Performance and Market Response

Despite the challenges in its vaccine business, Sanofi reported overall sales of €12.4 billion ($14.4 billion) for the quarter, representing a 7% year-over-year increase. This performance has led the company to reaffirm its annual sales guidance, projecting high-single-digit growth compared to last year's 8.6% revenue boost.

The market responded positively to Sanofi's quarterly results, with the company's share price increasing by 4% by mid-morning on the day of the announcement. This uptick reflects investor confidence in Sanofi's ability to navigate the current market landscape, largely due to the continued success of Dupixent.